全文获取类型
收费全文 | 319174篇 |
免费 | 18645篇 |
国内免费 | 550篇 |
专业分类
耳鼻咽喉 | 4346篇 |
儿科学 | 11081篇 |
妇产科学 | 10801篇 |
基础医学 | 48607篇 |
口腔科学 | 7788篇 |
临床医学 | 26925篇 |
内科学 | 59732篇 |
皮肤病学 | 6525篇 |
神经病学 | 23062篇 |
特种医学 | 12334篇 |
外国民族医学 | 44篇 |
外科学 | 49363篇 |
综合类 | 8204篇 |
现状与发展 | 1篇 |
一般理论 | 181篇 |
预防医学 | 22242篇 |
眼科学 | 7259篇 |
药学 | 22520篇 |
28篇 | |
中国医学 | 851篇 |
肿瘤学 | 16475篇 |
出版年
2021年 | 3009篇 |
2019年 | 3102篇 |
2018年 | 4801篇 |
2017年 | 3429篇 |
2016年 | 4039篇 |
2015年 | 4560篇 |
2014年 | 5863篇 |
2013年 | 8937篇 |
2012年 | 10886篇 |
2011年 | 10893篇 |
2010年 | 7352篇 |
2009年 | 6597篇 |
2008年 | 9931篇 |
2007年 | 10806篇 |
2006年 | 10487篇 |
2005年 | 10076篇 |
2004年 | 9626篇 |
2003年 | 8904篇 |
2002年 | 8454篇 |
2001年 | 13474篇 |
2000年 | 13832篇 |
1999年 | 11595篇 |
1998年 | 3231篇 |
1997年 | 2954篇 |
1996年 | 2739篇 |
1995年 | 2659篇 |
1994年 | 2417篇 |
1992年 | 8376篇 |
1991年 | 8509篇 |
1990年 | 8320篇 |
1989年 | 8146篇 |
1988年 | 7351篇 |
1987年 | 7117篇 |
1986年 | 6749篇 |
1985年 | 6540篇 |
1984年 | 4802篇 |
1983年 | 4150篇 |
1982年 | 2522篇 |
1979年 | 4442篇 |
1978年 | 3245篇 |
1977年 | 2744篇 |
1976年 | 2521篇 |
1975年 | 2854篇 |
1974年 | 3359篇 |
1973年 | 3369篇 |
1972年 | 3132篇 |
1971年 | 2951篇 |
1970年 | 2845篇 |
1969年 | 2586篇 |
1968年 | 2547篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
In clinical and epidemiological studies, there is a growing interest in studying the heterogeneity among patients based on longitudinal characteristics to identify subtypes of the study population. Compared to clustering a single longitudinal marker, simultaneously clustering multiple longitudinal markers allow additional information to be incorporated into the clustering process, which reveals co-existing longitudinal patterns and generates deeper biological insight. In the current study, we propose a Bayesian consensus clustering (BCC) model for multivariate longitudinal data. Instead of arriving at a single overall clustering, the proposed model allows each marker to follow marker-specific local clustering and these local clusterings are aggregated to find a global (consensus) clustering. To estimate the posterior distribution of model parameters, a Gibbs sampling algorithm is proposed. We apply our proposed model to the primary biliary cirrhosis study to identify patient subtypes that may be associated with their prognosis. We also perform simulation studies to compare the clustering performance between the proposed model and existing models under several scenarios. The results demonstrate that the proposed BCC model serves as a useful tool for clustering multivariate longitudinal data. 相似文献
3.
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
6.
7.
8.
9.
10.